Preview Mode Links will not work in preview mode

This Week in Cardiology

Oct 22, 2021

Aspirin for primary prevention, induced hypothermia, half-dose DOAC, and social media, are the topics John Mandrola, MD, discusses in this week’s podcast. To read a partial transcript or to comment, visit:

I - ASA for Primary Prevention

- USPSTF Rules Out Aspirin for Over 60s in Primary CVD Prevention

- Aspirin Use to Prevent Cardiovascular Disease: Preventive Medication

- Use of aspirin to reduce risk of initial vascular events in patients at moderate risk of cardiovascular disease (ARRIVE): a randomised, double-blind, placebo-controlled trial

- Effects of Aspirin for Primary Prevention in Persons with Diabetes Mellitus

- Effect of Aspirin on Cardiovascular Events and Bleeding in the Healthy Elderly

- Effect of Aspirin on All-Cause Mortality in the Healthy Elderly

II - Induced Hypothermia

- No Benefit From Lower Temps for Out-of-Hospital Cardiac Arrest

- The CAPITAL CHILL Randomized Clinical Trial

- Targeted Temperature Management at 33°C versus 36°C after Cardiac Arrest

- Hypothermia versus Normothermia after Out-of-Hospital Cardiac Arrest

III - Half-dose DOAC

- Half-Dose DOACs Cut Bleeding, Thrombus Risk Post-Watchman LAA Closure

- Half-Dose Direct Oral Anticoagulation Versus Standard Antithrombotic Therapy After Left Atrial Appendage Occlusion

IV - Social Media

- Navigating Benefits, Pitfalls of Social Media as a Female Doctor

- Gender Differences in Physician Use of Social Media for Professional Advancement


- USPSTF Statement on Aspirin: Poor Messaging at Best

You may also like:

Medscape editor-in-chief Eric Topol, MD, and master storyteller and clinician Abraham Verghese, MD, on Medicine and the Machine

The Bob Harrington Show with Stanford University Chair of Medicine, Robert A. Harrington, MD.

Questions or feedback, please contact